Jefferies Cuts Price Target on Deckers Outdoor (DECK) Following F4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sterne Agee CRT Reiterates Buy Following Deckers Outdoor (DECK) FQ4 Results
May 29, 2015 8:11 AM EDTSterne Agee CRT reiterates a Buy rating and $90 price target on Deckers Outdoor (NASDAQ: DECK) following Q4. DECK reported EPS of $0.04 versus estimates of $0.00. Revenue increased 15.6% versus estimates of +9.9%. Analyst Sam Poser said that DECK's brands are showing strength.
Poser commented, "Deckerss brands are showing strength and diversity across the board. UGGs strength is well beyond Classics;... More
After-Hours Stock Movers 05/28: (HRTX) (STML) (GME) (BLOX) Higher; (DECK) (CLLS) Lower (more...)
May 28, 2015 5:51 PM EDTHeron Therapeutics, Inc. (Nasdaq: HRTX) 39.8% HIGHER; announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Companys 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
Deckers Outdoor (DECK) Tops Q4 EPS by 4c; Issues Mixed Q1, FY16 Guidance
May 28, 2015 4:07 PM EDTDeckers Outdoor (NASDAQ: DECK) reported Q4 EPS of $0.04, $0.04 better than the analyst estimate of $0.00. Revenue for the quarter came in at $340.6 million versus the consensus estimate of $321.59 million.
Deckers Outdoor sees FY2016 EPS of $5.60, versus the consensus of $5.05. Deckers Outdoor sees FY2016 revenue of... More
Canaccord Genuity Reiterates Buy Ahead of Deckers Outdoor (DECK) Q4 Results
May 28, 2015 10:16 AM EDTCanaccord Genuity reiterates a Buy rating and $84 price target on Deckers Outdoor (NASDAQ: DECK) leading up to its FQ4 results. Analyst Camilo Lyon is expecting breakeven EPS on sales growth of 8%. DECK is scheduled to report its FQ4 earnings after market closes today.
Lyon commented, "We are modeling breakeven EPS (in line with consensus) on sales growth of 8% vs. consensus of 9%.... More
Trading Radar for 5/28: Avago (AVGO), OmniVision (OVTI), GameStop (GME), Express (EXPR), Dangdang (DANG) Report
May 27, 2015 2:47 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
Abercrombie & Fitch (NYSE: ANF) - consensus loss $0.34
Agilysys, Inc. (Nasdaq: AGYS) - consensus loss $0.04
American Superconductor (Nasdaq: AMSC) - consensus loss $0.70
Auris Medical Holding (Nasdaq: EARS) - consensus loss $0.22
China Xiniya... More
